TriangleAtezolizumab (NCT05001880)
Atezolizumab trial for Peritoneal Malignant Mesothelioma (NCT05001880). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated malignant peritoneal mesothelioma. Well-differentiated papillary and multicystic variants are excluded.
The idea: compare carboplatin, pemetrexed and bevacizumab with or without atezolizumab. Chemotherapy interferes with tumor growth; bevacizumab limits new blood vessels, while atezolizumab supports immune attack. Four intravenous treatment cycles may precede tumor-removal surgery and heated abdominal chemotherapy. Patients unsuitable for surgery may receive maintenance therapy.
This phase 2 study plans 66 patients. Aaron Mansfield leads the NCI-sponsored trial, with 38 recruiting US sites. Researchers compare tumor responses.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.